882847-34-9 | Fmoc-N-amido-PEG6-acid

Packsize	Purity	Availability	Price	Discounted Price
1g	97%	in stock	$63.00	$44.00
5g	97%	in stock	$258.00	$180.00

Description

• Catalog Number: AB98752
• Chemical Name: Fmoc-N-amido-PEG6-acid
• CAS Number: 882847-34-9
• Molecular Formula: C30H41NO10
• Molecular Weight: 575.6472
• MDL Number: MFCD06656474
• SMILES: OC(=O)CCOCCOCCOCCOCCOCCOCCNC(=O)OCC1c2ccccc2c2c1cccc2

Computed Properties

• Complexity: 689
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 41
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 24
• XLogP3: 1.7

Upstream Synthesis Route

Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid offers a versatile and powerful tool in the realm of chemical synthesis. This specialized compound plays a crucial role in peptide synthesis, particularly in solid-phase peptide synthesis (SPPS) methodology. The Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid serves as a key building block for incorporating specific functionalities and properties into peptides, allowing for precise control and customization of peptide sequences.Furthermore, the unique structure of Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid imparts enhanced stability and solubility characteristics, making it a favored choice in peptide chemistry. Its compatibility with Fmoc-based protecting groups ensures efficient and selective deprotection steps during peptide assembly, facilitating the synthesis of complex peptide structures with high purity and yield.In addition to its significance in peptide chemistry, Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid finds application in bioconjugation reactions, drug development, and materials science, highlighting its broad utility across diverse research areas. Overall, this compound embodies a valuable asset for researchers and professionals seeking to explore the intricate world of chemical synthesis and peptide design.

Literature

• Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent.

  International journal of nanomedicine 20120101